502 related articles for article (PubMed ID: 17077809)
1. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
2. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
[TBL] [Abstract][Full Text] [Related]
3. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
4. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
[TBL] [Abstract][Full Text] [Related]
5. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
[TBL] [Abstract][Full Text] [Related]
6. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
[TBL] [Abstract][Full Text] [Related]
7. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
8. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
Nordström AL; Farde L
J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
[TBL] [Abstract][Full Text] [Related]
9. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
10. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
11. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
Vernaleken I; Siessmeier T; Buchholz HG; Härtter S; Hiemke C; Stoeter P; Rösch F; Bartenstein P; Gründer G
Int J Neuropsychopharmacol; 2004 Dec; 7(4):421-30. PubMed ID: 15683553
[TBL] [Abstract][Full Text] [Related]
12. Effect of endogenous dopamine on extrastriatal [¹¹C]FLB 457 binding measured by PET.
Okauchi T; Suhara T; Maeda J; Kawabe K; Obayashi S; Suzuki K
Synapse; 2001 Aug; 41(2):87-95. PubMed ID: 11400175
[TBL] [Abstract][Full Text] [Related]
13. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
[TBL] [Abstract][Full Text] [Related]
14. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
15. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
16. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.
Talvik M; Nordström AL; Nyberg S; Olsson H; Halldin C; Farde L
Am J Psychiatry; 2001 Jun; 158(6):926-30. PubMed ID: 11384901
[TBL] [Abstract][Full Text] [Related]
17. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
19. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
20. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.
Takano A; Suhara T; Kusumi I; Takahashi Y; Asai Y; Yasuno F; Ichimiya T; Inoue M; Sudo Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):75-81. PubMed ID: 16040180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
